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Abstract
There are growing concerns about the emergence of resistance of
Sarcoptes scabiei to permethrin and other pyrethroid derivatives.
Sarcoptes scabiei mites collected from 40 patients visiting two
hospitals near Paris, France, were genotypically characterized
considering two parts of their voltage-sensitive sodium channel
gene. No nucleotide polymorphism resulting in a codon change at
codon 733 or other positions associated with knockdown
resistance in other arthropods has been identiﬁed. These data
may establish a reference line for future surveys of the suscep-
tibility of S. scabiei in the area.
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Scabies is an ectoparasitic infection caused in humans by the
mite Sarcoptes scabiei var. hominis [1–3]. Scabies remains a
signiﬁcant public health problem worldwide and is the most
common skin disease seen in developing countries [4]. The
worldwide prevalence is not known but has been estimated to
be 100–300 million cases. The classic manifestation of scabies
is generalized itching resulting in sleep loss. Complications,
usually due to secondary bacterial infections caused by group
A streptococci and Staphylococcus aureus, occur more fre-
quently in developing countries where scabies has been
associated with impetigo, post-streptococcal glomerulonephri-
tis and acute rheumatic fever [4].
Permethrin 5% cream is the ﬁrst-line treatment of
classical scabies in many countries [2,3,5]. Other main
treatments are benzyl benzoate 10–25%, crotamiton or oral
ivermectin. In France, permethrin 5% cream is not marketed
but esdepalletrin (Spregal), another pyrethroid compound,
is used as a topical acaricide against classical scabies.
Moreover, a combination of neopynamine and sumithrine
(A-PAR), two synthetic pyrethroids, is used as a disinfect-
ing agent for objects with which infected persons may have
come into contact. Pyrethroid compounds disrupt the
function of voltage-sensitive sodium channels (Vssc) of
arthropods, causing prolonged depolarization of nerve-cell
membranes and disrupting neurotransmission [6,7]. The
intensive use of pyrethroids worldwide over the last
30 years has led to the development of resistance in many
arthropods [6,8]. Target site insensitivity due to single
nucleotide polymorphisms (SNPs) has been demonstrated to
play a major role in conferring resistance to pyrethroids in
some arthropods. Clinical assessment of treatment failure in
scabies is problematic, particularly because of frequent
re-infestations [9]. In vitro studies have shown that suscep-
tibility of S. scabiei to permethrin is progressively reduced
with repeated administration [10]. In addition, Pasay et al.
identiﬁed an SNP at codon 733 (corresponding to the SNP
G1535D of the houseﬂy sequence) in the Vssc gene, which
was associated with in vivo and in vitro permethrin resistance
in a population of scabies mites (S. scabiei var. canis) [11].
The aim of this study was to search for the presence of the
G733D mutation or other SNPs in the Vssc gene in scabies
mites collected in consecutive scabies patients who came to
two French centres between September 2012 and April
2013. Currently, there are no such published data on
scabies mites collected in Europe or elsewhere in the world,
except in Australia.
Multiple superﬁcial skin samples were obtained from charac-
teristic lesions. The specimens showing adult mites and larval
stages on microscopic examination were conserved at 20°C
until further analysis. The DNA of each mite was individually
extracted as previously described [12]. Two domains of the kdr
gene were ampliﬁed using a nested approach. Two sets of
primers were used to amplify Domain 2, Segments 4–6 (D2F:
ATGATGAAATTGATGGCTCT; D2R: TGTGTTTGATCCA
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TTTACCA; D2NF: ATTTTCGTGAAGGATGGAAT; D2NR:
CTTTTTGGTATCCGCACTTT). Another two sets of primers
were used to amplify Domain 3, Segment 6 (D3F: GTATC
GATGCGAAAACAAA; D3R: GCGATGAAAAGCATAAT
GA; D3NF: TCGATAATGTTCTCAATGCCTA; D3NR: CA
TCTTTTTCATTGCGTTGTA). For each sample, 25-lL reac-
tionmixtureswere prepared containing 19 PCRbuffer, 200 lM
of each dNTP, 100 nM of each primer and 1.25 U of AmpliTaq
Gold (Applied Biosystems, Courtaboeuf, France). For ampliﬁ-
cation, 5 lL of DNA sample for the ﬁrst PCR and 2 lL for
nested PCR were used under the following conditions: 94°C
for 5 min, followed by 35 cycles of 94°C for 30 s, 52°C (56°C for
nested PCR) for 40 s and 72°C for 60 s. Only isolates showing
only one band by electrophoresis on 1.5% agarose gels (687 bp
forDomain 2 and 399 bp forDomain 3)were sequenced. Amino
acid sequences were compared with S. scabiei var. hominis Vssc
gene (GenBank accession number: DQ077148.4). The presence
of SNPs was conﬁrmed by reading both strands.
The protocol was reviewed and approved by the
Comite de Protection des Personnes (institutional review
board) of the ethics committee CPP-Ile-de-France X (23
October 2012). Informed consent was obtained from all
patients.
Complete sequences of the two domains were obtained
for 36 adult mites and four larval mites (one adult or larval
stage mite per patient). All scabies mites of our series had
homozygous wild-type Vssc gene in the sequenced domains,
and no nucleotide polymorphism resulting in a codon change
at codon 733 or other positions associated with knockdown
resistance in other arthropods has been identiﬁed. Several
hypotheses may explain our results. First, all scabies mites of
our series carried wild-type Vssc alleles associated with
susceptibility to pyrethroid derivatives [11]. This hypothesis
appears plausible because the drug pressure exerted by
esdepalletrin in France is weak [13]. Topical benzyl benzoate
and oral ivermectin are preferred treatments and the drug
pressure due to the combination of neopynamine and
sumithrine is difﬁcult to estimate. Second, SNP(s) in the Vssc
gene were present but not in the parts of the gene that we
have sequenced. A limitation of the present study is that we
have not sequenced the whole Vssc gene. We chose to
sequence the parts of the gene where most SNPs associated
with kdr resistance in S. scabiei or in other arthropods have
been identiﬁed (Fig. 1) [6–8,11,12,14]. Third, the resistance
to pyrethroid derivatives cannot be detected by SNP(s) in the
Vssc gene because this gene plays no major role in the
resistance of S. scabiei var. hominis. At present, such an
association was reported for S. scabiei var. canis following
many years on the host under permethrin pressure, but is
not yet reported for the human variety of scabies mites [11].
Pasay et al. [10] have shown (but also in S. scabiei var. canis)
that metabolic degradation by hyperproduction of enzymes
may participate in resistance to pyrethroids but this mech-
anism of resistance does not rule out a role for Vssc gene
mutations.
As experts in the ﬁeld advocate for the use of topical
permethrin in France and at a time when esdepalletrin is
increasingly used because topical benzyl benzoate is currently
out of stock and not manufactured in Europe, the issue of
emerging drug resistance in scabies is an increasing concern.
The lack of a kdr mutant observed in our series may establish a
reference line for future surveys of the susceptibility of
S. scabiei in the area.
FIG. 1. Location of main mutations associated with pyrethroid
resistance in domains II and III of the voltage-sensitive sodium channel
documented in different arthropod species (numbered according to
their position in the amino acid sequence of Musca domestica Vssc;
GenBank accession number: U38813). The G1535D mutation of the
houseﬂy sequence corresponds to the G733D mutation of dog mites
(Sarcoptes scabiei var. canis). M918V: Bemisia tabaci; M918T: Musca
domestica, Haematobia irritans; L925I: Bemisia tabaci; T929I: Pediculus
capitis; L932F: Pediculus capitis; L1014S: Anopheles gambiae, Culex pipiens;
L1014F:Anopheles gambiae, Blatella germanica, Culex pipiens, Haematobia
irritans, Leptinotarsa decemlineata, Musca domestica, Myzus persicae,
Plutella xylostella; L1014H: Heliothis virescens; M1524I: Drosophila mela-
nogaster; F1538I: Boophilus microplus; F1532L: Varroa destructor;
G1535D: Musca domestica (based upon Soderlund and Knipple, 2003
[6]).
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